BriaCell
Business Services · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Bellevue Ctr, 235 15th St Suite 300, Van...Phone Number
(604) 921-1810Website
www.briacell.comRevenue
-Stock Symbol
BCTXIndustry
About BriaCell
BriaCell Org Chart
Is BriaCell your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if BriaCell had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at BriaCell
Product Launch: Get notified when BriaCell launches new products
Website visits: Recent activity has been detected on your website
Check if BriaCell has recently received funding, and reach out quickly before it becomes old news!
Check out if BriaCell is spiking on competitors!
Earning: See what the market has to say on BriaCell recently announced quarterly report
BriaCell, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once BriaCell has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to BriaCell
Compare insights from companies similar to BriaCell, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BriaCell is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
BriaCell is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about BriaCell.
BriaCell financials insights
Gather financial insights about BriaCell, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Debt
$265K
Stock Offering
$59.5M
Share Placement
$4M
Share Placement
$5M
BriaCell Tech Stack
A closer look at the technologies used by BriaCell
Most Recent Scoops
BriaCell News & Media
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug (IND) application for Bria-PROS+ and issued a Study May Proceed letter, clearing the way for clinical evaluaBriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that the Odette Cancer Centre at Sunnybrook Health Sciences Centre, a leading cancer center in Toronto, Ontario, Canada, has joined BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhBriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™
PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces a manufacturing arrangement with FUJIFILM Biotechnologies California, a leading contract development and manufacturing organization (CDMO) specializing in cell therapies, to support the ongoing pivotal Phase 3 clinical dBriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™
PHILADELPHIA and VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that it has engaged Charles River Associates (CRA) (Nasdaq: CRAI) and Kaleio, Inc. to support commercial strategy, market access evaluation and brand planning for Bria-IMT.
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BriaCell
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for b... Read More

